Skip to main content

Pharmacopeia To Trade Under Accelrys Symbol on Nasdaq

NEW YORK, Feb. 27 (GenomeWeb News) - Pharmacopeia will begin trading on the Nasdaq today under the ticker symbol "ACCL," the company said yesterday. The change comes as Pharmacopeia prepares to take on the name "Accelrys" as part of a planned reorganization that includes the spin-off of its drug discovery unit.

 

The company announced its spin-off plan in December. Pharmacopeia's drug discovery unit will become a separate company with the name Pharmacopeia Drug Discovery, while the original company will continue to operate the Accerlys software business under the Accelrys name. The company said yesterday that it will request approval of the name change at its upcoming 2004 stockholder meeting. Meanwhile, PPD has applied for a listing on the Nasdaq National Market under the ticker symbol "PCOP."

 

The spin-off is expected to formally take place by the end of the present quarter, Pharmacopeia said.

 

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.